- 
             Something wrong with this record ?
 
DNA interactions of monofunctional organometallic osmium(II) antitumor complexes in cell-free media
H. Kostrhunova, J. Florian, O. Novakova, A.F. Peacock, P.J. Sadler, V. Brabec
Language English Country United States
        Grant support
          
              NR8562 
          
      MZ0   
          
            CEP Register  
          
      
      
    PubMed
          
           18494458
           
          
          
    DOI
          
           10.1021/jm701538w
           
          
          
  
    Knihovny.cz E-resources
    
  
              
      
- MeSH
- DNA Adducts chemistry MeSH
- Cell-Free System MeSH
- Drug Resistance, Neoplasm MeSH
- Cisplatin chemistry MeSH
- DNA chemistry metabolism MeSH
- Ethidium MeSH
- Financing, Organized MeSH
- Fluorescent Dyes MeSH
- Spectrometry, Fluorescence MeSH
- Intercalating Agents MeSH
- Humans MeSH
- Molecular Conformation MeSH
- Cell Line, Tumor MeSH
- Oligonucleotides chemistry MeSH
- Organometallic Compounds chemistry metabolism MeSH
- Osmium MeSH
- Antineoplastic Agents chemistry metabolism MeSH
- Drug Screening Assays, Antitumor MeSH
- DNA, Superhelical chemistry MeSH
- Transition Temperature MeSH
- Structure-Activity Relationship MeSH
- Check Tag
- Humans MeSH
This work is the first in-depth study of osmium binding to DNA and confirms the pharmacological activity of a new class of anticancer metallodrugs. We investigated the interactions between the potential biological target DNA and four osmium(II) arene complexes, of the type [(eta 6-arene)Os(LL)Cl]n+, where arene = biphenyl or p-cymene and LL = ethylenediamine, picolinate, or oxinate in an effort to understand their mechanism of action. Most notably we show that these complexes bind to DNA. DNA adducts of the OsII complexes that exhibit promising cytotoxic effects in ovarian tumor cell lines largely distort its conformation. The data are consistent with DNA binding of the complexes containing biphenyl as the arene ligand that involves combined coordination to guanine residues and noncovalent interactions between the arene ligand and DNA. The results also indicate both a mechanism of action and a detoxification mechanism for OsII arene compounds different from those of cisplatin.
References provided by Crossref.org
- 000
- 03047naa 2200541 a 4500
- 001
- bmc11003869
- 003
- CZ-PrNML
- 005
- 20250114103542.0
- 008
- 110302s2008 xxu e eng||
- 009
- AR
- 024 __
- $a 10.1021/jm701538w $2 doi
- 035 __
- $a (PubMed)18494458
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kostrhunová, Hana. $7 _AN047101
- 245 10
- $a DNA interactions of monofunctional organometallic osmium(II) antitumor complexes in cell-free media / $c H. Kostrhunova, J. Florian, O. Novakova, A.F. Peacock, P.J. Sadler, V. Brabec
- 314 __
- $a Institute of Biophysics, Academy of Sciences of the Czech Republic, vvi, Kralovopolska 135, CZ-61265 Brno, Czech Republic.
- 520 9_
- $a This work is the first in-depth study of osmium binding to DNA and confirms the pharmacological activity of a new class of anticancer metallodrugs. We investigated the interactions between the potential biological target DNA and four osmium(II) arene complexes, of the type [(eta 6-arene)Os(LL)Cl]n+, where arene = biphenyl or p-cymene and LL = ethylenediamine, picolinate, or oxinate in an effort to understand their mechanism of action. Most notably we show that these complexes bind to DNA. DNA adducts of the OsII complexes that exhibit promising cytotoxic effects in ovarian tumor cell lines largely distort its conformation. The data are consistent with DNA binding of the complexes containing biphenyl as the arene ligand that involves combined coordination to guanine residues and noncovalent interactions between the arene ligand and DNA. The results also indicate both a mechanism of action and a detoxification mechanism for OsII arene compounds different from those of cisplatin.
- 650 _2
- $a protinádorové látky $x chemie $x metabolismus $7 D000970
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a bezbuněčný systém $7 D002474
- 650 _2
- $a cisplatina $x chemie $7 D002945
- 650 _2
- $a DNA $x chemie $x metabolismus $7 D004247
- 650 _2
- $a adukty DNA $x chemie $7 D018736
- 650 _2
- $a superhelikální DNA $x chemie $7 D004278
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a screeningové testy protinádorových léčiv $7 D004354
- 650 _2
- $a ethidium $7 D004996
- 650 _2
- $a fluorescenční barviva $7 D005456
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a interkalátory $7 D007364
- 650 _2
- $a molekulární konformace $7 D008968
- 650 _2
- $a oligonukleotidy $x chemie $7 D009841
- 650 _2
- $a organokovové sloučeniny $x chemie $x metabolismus $7 D009942
- 650 _2
- $a osmium $7 D009992
- 650 _2
- $a fluorescenční spektrometrie $7 D013050
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a tranzitní teplota $7 D044366
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Florián, Jakub $7 xx0327833
- 700 1_
- $a Nováková, Olga, $d 1966- $7 xx0072650
- 700 1_
- $a Peacock, Anna F.
- 700 1_
- $a Sadler, Peter J.
- 700 1_
- $a Brabec, Viktor, $d 1944- $7 jo20010087133
- 773 0_
- $t Journal of Medicinal Chemistry $w MED00010049 $g Roč. 51, č. 12 (2008), s. 3635-3643 $x 0022-2623
- 910 __
- $a ABA008 $b x $y 6 $z 0
- 990 __
- $a 20110407110847 $b ABA008
- 991 __
- $a 20250114103539 $b ABA008
- 999 __
- $a ok $b bmc $g 831210 $s 695893
- BAS __
- $a 3
- BMC __
- $a 2008 $b 51 $c 12 $d 3635-3643 $i 0022-2623 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
- GRA __
- $a NR8562 $p MZ0
- LZP __
- $a 2011-3B/irme
